Pharmacotherapy for tonic–clonic seizures

Bibliography

• Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011;10:446-56
   PubMed Web of Science ®Google Scholar
• Lawn ND, Bamlet WR, Radhakrishnan K, et al. Injuries due to seizures in persons with epilepsy: a population-based study. Neurology 2004;63:1565-70
   PubMed Web of Science ®Google Scholar
• Tiamkao S, Shorvon SD. Seizure-related injury in an adult tertiary epilepsy clinic. Hong Kong Med J 2006;12:260-3
   PubMedGoogle Scholar
• Alper K, Kuzniecky R, Carlson C, et al. Postictal psychosis in partial epilepsy: a case-control study. Ann Neurol 2008;63:602-10
   PubMed Web of Science ®Google Scholar
• Hoppe C, Elger CE. Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol 2011;7:462-72
   PubMed Web of Science ®Google Scholar
• Hesdorffer DC, Tomson T, Benn E, et al. Do antiepileptic drugs or generalized tonic-clonic seizure frequency increase SUDEP risk? A combined analysis. Epilepsia 2012;53:249-52
   PubMed Web of Science ®Google Scholar
• Shorvon S, Tomson T. Sudden unexpected death in epilepsy. Lancet 2011, doi:10.1016/S0140-6736
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol 2011;10:961-8
   PubMed Web of Science ®Google Scholar
• Blume WT, Luders HO, Mizrahi E, et al. Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia 2001;42:1212-18
   PubMedGoogle Scholar
• Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17
   PubMed Web of Science ®Google Scholar
• Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983;33:1487-9
   PubMed Web of Science ®Google Scholar
• Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006;129:1281-92
   PubMed Web of Science ®Google Scholar
• Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 2007;6:793-804
   PubMed Web of Science ®Google Scholar
• Marson AG, Williamson PR. Interpreting regulatory trials in epilepsy. Curr Opin Neurol 2009;22:167-73
   PubMed Web of Science ®Google Scholar
• Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 2005;46(Suppl 9):161-8
   PubMed Web of Science ®Google Scholar
• The diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE 2012. Available from: http://guidance.nice.org.uk/CG137/NICEGuidance/pdf/English [Last accessed 17 August 2013]
   Google Scholar
• Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54:551-63
   PubMed Web of Science ®Google Scholar
• Rheims S, Perucca E, Cucherat M, Ryvlin P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 2011;52:219-33
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1016-26
   PubMed Web of Science ®Google Scholar
• Mohanraj R, Brodie MJ. Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting. Acta Neurol Scand 2007;115:204-8
   PubMed Web of Science ®Google Scholar
• Diagnosis and Management of Epilepsy in Adults. A national clinical guidelines. SIGN 2005. Available from: http://www.sign.ac.uk/guidelines/fulltext/70/ [Last accessed 23 February 2014]
   Google Scholar
• Knake S, Hamer HM, Schomburg U, et al. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure 1999;8:314-17
   PubMed Web of Science ®Google Scholar
• Gamble C, Williamson PR, Chadwick DW, Marson AG. A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology 2006;66:1310-17
   PubMed Web of Science ®Google Scholar
• Marson AG, Williamson PR, Hutton JL, et al. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst Rev 2000(3):CD001030
   PubMedGoogle Scholar
• Nolan SJ, Marson AG, Pulman J, Tudur Smith C. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database Syst Rev 2013;8:CD001769
   PubMedGoogle Scholar
• Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26:451-60
   PubMed Web of Science ®Google Scholar
• Ramsay E, Faught E, Krumholz A, et al. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia 2010;51:1970-7
   PubMed Web of Science ®Google Scholar
• Malafosse A, Genton P, Hirsch E, et al. Idiopathic generalised epilepsies: clinical, experimental and genetic. John Libbey and Co., Eastleigh; 1994
   Google Scholar
• A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures. NCT01969851. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01969851?term=lacosamide+epilepsy&rank=5 [Last accessed 20 February 2014]
   Google Scholar
• A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures. NCT01747915. Available from: http://clinicaltrials.gov/ct2/show/NCT01747915?term=pregabalin+primary+generalized&rank=1 [Last accessed 20 February 2014]
   Google Scholar
• A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures. NCT01393743. Available from: http://clinicaltrials.gov/ct2/show/NCT01393743?term=perampanel+generalized&rank=1 [Last accessed 20 February 2014]
   Google Scholar
• Beran RG, Berkovic SF, Dunagan FM, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 1998;39:1329-33
   PubMed Web of Science ®Google Scholar
• Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005;65:1737-43
   PubMed Web of Science ®Google Scholar
• Biton V, Di Memmo J, Shukla R, et al. Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. Epilepsy Behav 2010;19:352-8
   PubMed Web of Science ®Google Scholar
• Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007;69:1751-60
   PubMed Web of Science ®Google Scholar
• Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008;70:607-16
   PubMed Web of Science ®Google Scholar
• Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52:1330-7
   PubMed Web of Science ®Google Scholar
• Ben-menachem E. YTC-E Study Group. A double-blind trial of topiramate in patients with generalized tonic-clonic seizures of non-focal origin. Epilepsia 1997;30:60
   Google Scholar
• Chadwick D, Leiderman DB, Sauermann W, et al. Gabapentin in generalized seizures. Epilepsy Res 1996;25:191-7
   PubMed Web of Science ®Google Scholar
• Ohtahara S. Zonisamide in the management of epilepsy–Japanese experience. Epilepsy Res 2006;68(Suppl 2):S25-33
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Aikawa H. Efficacy of zonisamide: our experience. Seizure 2004;13(Suppl 1):S41-8. discussion S49
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Kelly K, Wilson EA, et al. A prospective audit of adjunctive zonisamide in an everyday clinical setting. Epilepsy Behav 2010;17:455-60
   PubMed Web of Science ®Google Scholar
• Marinas A, Villanueva V, Giraldez BG, et al. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. Epileptic Disord 2009;11:61-6
   PubMed Web of Science ®Google Scholar
• Ramaratnam S, Marson AG, Baker GA. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2001(3):CD001909
   Google Scholar
• Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-24
   PubMed Web of Science ®Google Scholar
• French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555-63
   PubMed Web of Science ®Google Scholar
• Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007;68:1197-204
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-17
   PubMed Web of Science ®Google Scholar
• Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51:958-67
   PubMed Web of Science ®Google Scholar
• Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-53
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Gabbai AA, Hufnagel A, et al. Efficacy and safety of Eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study. Epilepsia 2008;49:424-5
   Web of Science ®Google Scholar
• Elger C, Bialer M, Cramer JA, et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007;48:497-504
   PubMed Web of Science ®Google Scholar
• Elger C, Halasz P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50:454-63
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Lopes-Lima J, Almeida L, et al. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009;120:281-7
   PubMed Web of Science ®Google Scholar
• Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-42
   PubMed Web of Science ®Google Scholar
• Shorvon S, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000;41:1179-86
   PubMed Web of Science ®Google Scholar
• Elger CE, Brodie MJ, Anhut H, et al. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005;46:1926-36
   PubMed Web of Science ®Google Scholar
• French JA, Kugler AR, Robbins JL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60:1631-7
   PubMed Web of Science ®Google Scholar
• Lee BI, Yi S, Hong SB, et al. Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: a double-blind, randomized, placebo-controlled, multicenter trial. Epilepsia 2009;50:464-74
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589-96
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54:117-25
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-15
   PubMed Web of Science ®Google Scholar
• Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: Systematic review and meta-analysis. Epilepsia 2010;51(1):7-26
   PubMed Web of Science ®Google Scholar
• Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38:859-80
   PubMed Web of Science ®Google Scholar
• Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 2001;46:259-70
   PubMed Web of Science ®Google Scholar
• Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005;28:72-8
   PubMed Web of Science ®Google Scholar
• Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362:790-9
   PubMed Web of Science ®Google Scholar
• Trudeau V, Myers S, LaMoreaux L, et al. Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 1996;11:470-5
   PubMed Web of Science ®Google Scholar
• A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs. SANAD –II. Available from: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=12477 [Last accessed 23 February 2014]
   Google Scholar
• Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-17
   PubMed Web of Science ®Google Scholar
• Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360:1597-605
   PubMed Web of Science ®Google Scholar
• Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013;80:400-5
   PubMed Web of Science ®Google Scholar
• Friedman D, French JA. Clinical trials for therapeutic assessment of antiepileptic drugs in the 21st century: obstacles and solutions. Lancet Neurol 2012;11:827-34
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Nashef L, Tomson T. Prevention of sudden unexpected death in epilepsy: a realistic goal? Epilepsia 2013;54(Suppl 2):23-8
   PubMed Web of Science ®Google Scholar
• Sperling MR, Greenspan A, Cramer JA, et al. Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epilepsia 2010;51:333-43
   PubMed Web of Science ®Google Scholar
• Halford JJ, Ben-Menachem E, Kwan P, et al. A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. Epilepsia 2011;52:816-25
   PubMed Web of Science ®Google Scholar
• Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000;41:1597-607
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50:1899-909
   PubMed Web of Science ®Google Scholar
• Biton V, Krauss G, Vasquez-Santana B, et al. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia 2011;52:234-42
   PubMed Web of Science ®Google Scholar
• Kalviainen R, Brodie MJ, Duncan J, et al. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group. Epilepsy Res 1998;30:31-40
   PubMed Web of Science ®Google Scholar
• Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 1998;55:56-62
   PubMedGoogle Scholar
• Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 1996;46:1678-83
   PubMed Web of Science ®Google Scholar
• Korean. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group. Epilepsia 1999;40:1767-74
   PubMed Web of Science ®Google Scholar
• Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24
   PubMed Web of Science ®Google Scholar
• Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996;46:1684-90
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43
   PubMed Web of Science ®Google Scholar
• Guberman A, Neto W, Gassmann-Mayer C. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002;106:183-9
   PubMed Web of Science ®Google Scholar
• French JA, Mosier M, Walker S, et al. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. Neurology 1996;46:54-61
   PubMed Web of Science ®Google Scholar
• Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993;15:67-73
   PubMed Web of Science ®Google Scholar